Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced orMetastatic Non-small Cell Lung Cancer with Actionable Genomic Alterationsand Progressed On or After Applicable Targeted Therapy and PlatinumbasedChemotherapy (TROPION-Lung05)

Daiichi Sankyo, Inc.0 个研究点目标入组 150 人开始时间: 2020年11月30日最近更新: 2022年8月8日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Daiichi Sankyo, Inc.
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects must meet all of the following criteria to be eligible for
•enrollment into the study:
•1. Sign and date the ICF prior to the start of any study- specific qualification procedures.
•2. Adults =18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements).
•3. Has pathologically documented NSCLC that:
•a. Is stage IIIB, IIIC or stage IV NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition).
•b. Has one or more of the following documented activating tumor genomic alterations: EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping or RET.
•4. Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC.
•5. Subject must meet the following for advanced or metastatic NSCLC:
•a. Has been treated with at least one but no more than two cytotoxic agent-containing therapy in the metastatic setting (please refer 5.1 section of Study Protocol)
•b. May have received up to one checkpoint inhibitor (CPI)-containing regimen (may be in combination with a cytotoxic agent as part of a regimen described in 5a above or as an additional CPI regimen without a cytotoxic agent);
•c. Has been treated with one or more lines of non-CPI targeted therapy that is locally approved for the subject's applicable genomic alteration at the time of screening; OR one or more of the agents specified in the table in section 5.1 of Protocol
•6. Must undergo a mandatory pre-treatment tumor biopsy procedure OR If available, a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the mandatory biopsy collected during screening. Results from this biopsy will not be used to determine eligibility for the study.
•7. Archival tumor tissue from initial diagnosis is required, to the extent that archival tumor tissue is available.
•8. Has measurable disease based on local imaging assessment using RECIST v1.1.
•9. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.
•10. Within 7 days before Cycle 1 Day 1, has adequate bone marrow function defined as:
•a. Platelet count =100,000/mm3 (platelet transfusion is not allowed within 1 week prior to screening assessment).
•b. Hemoglobin =9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
•c. Absolute neutrophil count =1500/mm3 (granulocyte-colony stimulating factor [G-CSF] administration is not allowed within 1 week prior to screening assessment).
•(See Section 6.5 and Section 6.7 for use of G-CSF and erythropoietin)
•11. Within 7 days before Cycle 1 Day 1, has
•- Adequate hepatic function, defined as:
•? Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 × upper limit of normal (ULN) or AST/ALT =5.0 x ULN if transferase elevation is due to liver metastases).
•? Total bilirubin (TBL) =1.5 × ULN or (<3.0 mg/dL in the presence of documented Gilbert's Syndrome [unconjugated hyperbilirubinemia]).
•? Moderate hepatic dysfunction (a maximum of 9 subjects): TBL >1.5 × ULN and =3 × ULN and any AST.
•Note:After a maximum of 9 subjects with moderate hepatic dysfunction have been enrolled, subsequent subjects with moderate hepatic dysfunction will be excluded.
•12. Within 7 days befor

排除标准

•Subjects who meet any of the following criteria will be disqualified from entering the study:
•1. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment.
•Note: A CT or magnetic resonance imaging (MRI) scan of the brain at baseline is required for all subjects. For those subjects in whom CNS metastases are first discovered at the time of screening, the treating investigator should consider delay of study treatment to document stability of CNS metastases with repeat imaging at least 4 weeks later (in which case, repeat of all screening activity may be required).
•2. Has leptomeningeal carcinomatosis.
•3. Prior treatment with:
•a. Any chemotherapeutic agent targeting topoisomerase I, including ADC
•containing such agent.
•b. TROP2-targeted therapy.
•4. Uncontrolled or significant cardiovascular disease, including:
•a. Mean QT interval corrected for heart rate using Fridericia's formula
•(QTcF) >470 milliseconds (msec) (based on the average of screening
•triplicate 12-lead ECG determinations).
•b. History of myocardial infarction within 6 months prior to Cycle 1 Day 1.
•c. History of uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1.
•d. Symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV) at screening. Subjects with a history of Class II to IV CHF prior to screening, must have returned to class I CHF and have LVEF =50% (by either an ECHO or MUGA scan within 28 days of Cycle 1 Day 1) in order to be eligible.
•e. History of serious cardiac arrhythmia requiring treatment.
•f. LVEF <50% or institutional lower limit of normal by ECHO or MUGA scan. within 28 days before Cycle 1 Day 1.
•g. Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) within 28 days before Cycle 1 Day 1.
•5. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
•6. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study Cycle 1 Day 1, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior pneumonectomy.
•7. Clinically significant corneal disease.
•8. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Note: Subjects with localized fungal infections of skin or nails are eligible.
•9. Has known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load, CD4+ counts/levels >250, no history of

研究者

发起方

Daiichi Sankyo, Inc.

相似试验

进行中（未招募）

1 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic AlterationsAdvanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-002774-27-FRDaiichi Sankyo, Inc.150

进行中（未招募）

2 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations

JPRN-jRCT2041200097Inoguchi Akihiro150

进行中（未招募）

1 期

EUCTR2020-002774-27-HUDaiichi Sankyo, Inc.150

招募中

2 期

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum-based Chemotherapy (TROPION-Lung05)10029107Non-Small cell Lung CancerNSCLC

NL-OMON51908Daiichi Sankyo, Inc.13

进行中（未招募）

1 期

EUCTR2020-002774-27-ITDAIICHI SANKYO INC.150